Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1680
    +0.0024 (+0.20%)
     

  • GBP/USD

    1.2493
    -0.0018 (-0.15%)
     

  • Bitcoin GBP

    51,251.21
    -471.44 (-0.91%)
     

  • CMC Crypto 200

    1,332.11
    -64.42 (-4.61%)
     

  • S&P 500

    5,108.24
    +59.82 (+1.18%)
     

  • DOW

    38,318.63
    +232.83 (+0.61%)
     

  • CRUDE OIL

    83.80
    +0.23 (+0.28%)
     

  • GOLD FUTURES

    2,349.90
    +7.40 (+0.32%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Pfizer and BioNTech's Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe Earlier

Brian Orelli, PhD, The Motley Fool
·2-min read
Pfizer and BioNTech's Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe Earlier

BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) are right on the heels of Moderna (NASDAQ: MRNA) in the race to potentially develop a messenger RNA (mRNA) vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19. In an interview with The Wall Street Journal, BioNTech CEO Ugur Sahin predicted the companies will have enough data for a vaccine to be ready for approval by December. The companies are still trying to figure out which of multiple vaccine candidates should be taken into a 30,000-patient phase 2/3 clinical trial that is scheduled to start this month.

Continue reading